Surmodics (Nasdaq:SRDX) announced today that it launched its most advanced hydrophilic medical device coating technology.
Eden Prairie, Minnesota-based Surmodics designed the Preside coatings to complement its existing Serene hydrophilic coatings. Preside offers a unique, low-friction and low-particulate generation coating. It further enhances distal access for neurovascular applications and improves crossing for coronary lesions or chronic total occlusions.
Surmodics said it formulated Preside coatings to meet the challenge of achieving the right balance of lubricity and coating durability. It allows customers to leverage their existing coating processes, resulting in easy implementation in a manufacturing environment.
The company said it applies the coatings using its patented Photolink UV curing process. This process covalently bonds surface treatments to substrates at ambient temperature.
“Hydrophilic coatings are an essential feature to help medical devices access and navigate tortuous vascular pathways, allowing physicians to reach distal treatment sites for improved therapeutic outcomes,” said Charlie Olson, SVP, and president of Surmodics’ medical device coatings business. “We are pleased to secure the first 510(k) device clearance that leverages this new technology. Our Preside hydrophilic coatings strengthen our existing portfolio and sets a new performance standard for the industry, and the medical device manufacturers we serve.”
It marks another positive development for Surmodics, which this year won FDA approval for its SurVeil drug-coated balloon (DCB).
